英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
graphicus查看　graphicus　在百度字典中的解释百度英翻中〔查看〕
graphicus查看　graphicus　在Google字典中的解释Google英翻中〔查看〕
graphicus查看　graphicus　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Metastatic colorectal cancer: ESMO Clinical Practice Guideline for . . .
    Figure 1 Management of mCRC potentially amenable to locoregional therapy Purple: algorithm title; blue: systemic anticancer therapy or their combination; turquoise: non-systemic anticancer therapies or combination of treatment modalities; white: other aspects of management and non-treatment aspects CEA, carcinoembryonic antigen; ChT, chemotherapy; CRLM, colorectal liver metastasis; dMMR, MMR
  • Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin . . .
    To investigate whether intermittent treatment after an induction phase of first-line schedule of fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus panitumumab (PAN) prevents or delays the onset of resistance and improves safety and compliance with treatment in patients with unresectable RAS BRAF wild-type (wt) metastatic colorectal cancer (mCRC)
  • ESMO 2026 Guideline: Redefining the Management of Metastatic Colorectal . . .
    Metastatic colorectal cancer (mCRC) represents a complex and biologically diverse disease in which treatment decisions increasingly depend on molecular characteristics, disease burden, and patient-specific factors
  • U. S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen . . .
    BRAFTOVI ® (encorafenib) is indicated, in combination with cetuximab and fluorouracil-based chemotherapy, for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-authorized test
  • Management of BRAF-mutant metastatic colorectal cancer: a review of . . .
    Herein, we review the clinical and translational literature on the role of the BRAF V600E mutation in the pathogenesis of mCRC, its mechanisms as a prognostic marker, and its potential utility as a predictive marker of treatment response We then summarize the current evidence-based recommendations for management of BRAF V600E-mutated mCRC, with a focus on recent clinical research advances in
  • Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer
    First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E–mutated metastatic colorectal cancer
  • Encorafenib, cetuximab and chemotherapy in BRAF-mutant . . . - Nature
    Encorafenib + cetuximab (EC) is approved for previously treated BRAF V600E-mutant metastatic colorectal cancer (mCRC) based on the BEACON phase 3 study Historically, first-line treatment of BRAF
  • FDA Approves Encorafenib Combination for BRAF V600E . . . - Pharmacy Times
    Encorafenib is an oral small molecule kinase inhibitor that targets BRAF V600E and is used for various cancer types It received initial approval in 2024 in combination with cetuximab and mFOLFOX6 (leucovorin calcium [folinic acid], fluorouracil, and oxaliplatin) for the treatment of patients with mCRC with a BRAF V600E mutation
  • FDA Grants Encorafenib Combo Traditional Approval in BRAF V600E+ mCRC
    The FDA has approved encorafenib (Braftovi) in combination with cetuximab (Erbitux) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) harboring a BRAF V600E mutation, as detected by an FDA-authorized test 1 This decision converts its previous accelerated approval in this indication
  • Metastatic colorectal cancer: ESMO Clinical . . . - Annals of Oncology
    This European Society for Medical Oncology (ESMO) Guideline describes improvements in diagnosis, staging and treatment of metastatic CRC (mCRC) patients, which have contributed to the current ‘state-of-the-art’ treatment approaches, and provides guidance for the comprehensive management of patients with mCRC





中文字典-英文字典  2005-2009